Life science and analytical instruments market seen doubling by 2035

Market Research Future says the global life science and analytical instruments market will grow from $23.35 billion in 2026 to $47.26 billion by 2035, driven by biologics pipelines, continuous-manufacturing rules and AI-enabled analytics. North America leads today, while Asia-Pacific is the fastest-growing region over the forecast period.

Why it matters: - The market is shifting from a one-time equipment purchase cycle to recurring demand tied to drug development, quality control and service contracts. - Biologics, continuous manufacturing and AI-powered workflows are expanding the number of tests, instruments and software platforms labs need. - The forecast points to steady demand through 2035, even if broader healthcare spending slows.

What happened: - Market Research Future projected the global life science and analytical instruments market will reach $47.26 billion by 2035, up from $23.35 billion in 2026. - The forecast implies an 8.15% compound annual growth rate from 2026 to 2035. - The market base was estimated at $21.68 billion in 2025. - The report was released July 8, 2026. - A free sample is available here. - The full report is available here.

The details: - Biologics pipelines topped 8,500 active candidates in 2024, up 14% year over year. - Phase II and later biologics typically require liquid chromatography-mass spectrometry testing, which supports recurring instrument demand. - FDA 2024 guidance on cell-therapy IND filings promotes orthogonal analytical methods, pushing sponsors and contract labs to buy multiple instruments. - A single monoclonal antibody can require 15 to 20 analytical tests, compared with 5 to 8 for a traditional tablet. - Large pharma R&D sites typically run 200 to 400 analytical instruments each, and those instruments need scheduled requalification. - ICH Q13, finalized in 2023, set expectations for continuous manufacturing and real-time process analytical technology monitoring. - Pfizer's continuous-manufacturing site in Freiburg, Germany, has more than 40 inline analytical sensors per production line. - Gas chromatography remains dominant in residual-solvent analysis, while ultra-high-performance liquid chromatography is gaining share in intact-protein and peptide-mapping workflows. - Machine-learning tools in chromatography data systems can reduce method-development time from weeks to hours. - Agilent's OpenLab CDS 2.8 update, released in Q3 2024, uses predictive retention-time modeling and reached 97% first-pass accuracy in validation studies. - Thermo Fisher's 2024 cloud-connected Orbitrap systems cut method-development timelines by 30% to 40% based on vendor benchmarks. - MIT's Accelerated Materials Discovery Lab reported 10x throughput gains using autonomous LC-MS workflows in 2024. - The report said autonomous analytical systems could account for 15% to 20% of new instrument installations in high-throughput pharma environments by 2030. - Chromatographs held about 31.2% of revenue share in 2025. - Spectrometers are the fastest-growing product segment, at 8.65% CAGR. - Liquid analyzers generated $3.14 billion in 2025. - Analytical X-ray and microscopy is projected to grow at 7.40% CAGR. - Clinical and diagnostics applications held the largest application share in 2025. - Research applications are the fastest-growing application segment. - The NIH's All of Us program has more than 500,000 enrolled participants. - Pharmaceutical and biotechnology companies accounted for about 63.5% of end-user share in 2025. - Biopharmaceutical and nutraceutical users are the fastest-growing end-user segment, at 9.35% CAGR. - Hospitals and diagnostic laboratories are adding portable Raman and near-infrared spectroscopy tools for decentralized testing. - North America held about 41.5% of the market in 2025. - The United States generated about 78% of North American revenue. - NIH funding topped $48.3 billion in fiscal 2025, supporting U.S. demand. - Europe was the second-largest region, at $5.85 billion in 2025. - Asia-Pacific is the fastest-growing region, at 9.67% CAGR. - China held about 38% of Asia-Pacific revenue. - India is projected to grow at 10.45% CAGR. - The Middle East and Africa is expected to grow at 7.45% CAGR. - South America reached $1.08 billion in 2025, with Brazil accounting for about 58% of regional revenue. - The market is moderately concentrated, with an estimated Herfindahl-Hirschman Index of 1,200 to 1,400. - The top five companies control 55% to 60% of revenue. - Agilent, Thermo Fisher, Waters, Danaher and Shimadzu are among the leading vendors. - Agilent's predictive retention-time modeling and Thermo Fisher's Orbitrap launches show how vendors are competing on software, speed and workflow integration. - Waters released BioResolve Protein A columns in June 2025 and said the product increased antibody-titer sensitivity by 7x. - Danaher said 65% of its life-science revenue comes from recurring streams.

Between the lines: - The strongest demand is coming from regulated workflows, not optional research spending, which should make the category less cyclical than many lab equipment markets. - Vendors are trying to lock in customers through software, consumables and service bundles, not just hardware performance. - AI and automation lower technical barriers for smaller labs, which could widen the customer base beyond top-tier pharma. - Regional growth is being shaped by policy, especially in the U.S., China and India, where funding and regulatory requirements are directly expanding instrument adoption.

What's next: - Adoption of autonomous and AI-assisted analytical systems is expected to rise through 2030 as labs push for faster turnaround and higher throughput. - Legacy batch facilities are likely to keep retrofitting process analytical technology to meet continuous-manufacturing expectations. - Integrated multi-omics platforms are expected to become more common in precision-medicine and translational research programs. - Competitive pressure should stay focused on interoperability, recurring revenue and platform integration rather than standalone instrument sales.

The bottom line: - The market’s next phase is being shaped by biologics, regulation and automation, with recurring demand likely to outlast short-term spending cycles.